FDAnews
www.fdanews.com/articles/138361-thallion-provides-update-on-phase-ii-shigatec-trial

Thallion Provides Update on Phase II Shigatec Trial

July 13, 2011
Thallion Pharmaceuticals announced it has temporarily suspended the screening and enrollment of the high dose cohort of its Phase II Shigatec study as a precautionary measure due to a preliminary product out-of-specification (OOS) finding observed during routine stability testing of its anti-Stx1 monoclonal antibody.
SYS-CON